Biopharma4.0 will not only tap into the transformation of the process and manufacturing mode of enterprises, but also that of biopharma R&D. We have also witnessed the revolutions of the biopharma industry over the past few years: enterprises of CDMO industry have sprung up like mushrooms with the return and startups of oversea Chinese talents and the landing of MAH system; WuXi AppTech, a leading enterprise of CDMO industry has sped up to catch up with the world's CDMO counterparts; the first monoclonal antibodies (mAbs) from local player has been approved and launched into the market, and antibody drug conjugates (ADCs) are gaining momentum in 2020. The products for precise and personalized treatment by tumor immunotherapy have been approved for commercialization one after another; There have been great changes in the domestic medical R&D; The domestic biopharma enterprises have grown from like a hundred flowers blooming together at the beginning into a ever-growing level of consolidation; Biopharma4.0 aims to probe into the transformation of the biopharma industry against the backdrop!

Conference Highlights

30+

Speakers

Top Higher-up 's output viewpoint, the latest trend, the most advanced technology application? The CIBP4.0 summit provides a platform for you to communicate with Top Higher-up

800+

Delegates

Accurate vertical guests in the biopharmaceutical industry, more than half of the precise guests from the field of biopharmaceutical R&D, process, production, clinical, etc., refuse to be big but not precise

50+

Sponsor partner

Sponsor seats, no matter your budget is large or small, we can provide you with a series of services-to ensure that the attending suppliers get the form of participation they want

1+1+1

Various event formats

1 Warm up + 1 gala dinner + 1 cocktail dinner before the conference, various ways to participate in the conference enable all guests to quickly become familiar with each other and communicate more deeply. Let the atmosphere of the meeting no longer be embarrassing

Hot Topic

Main Session

AI empowers pharmaceutical R&D

International trends on drug targets and new delivery mechanisms
Display of scientific research achievements of innovative pharmaceutical enterprises and KOLs
Pioneers of License in & Out sharing practices and experience in avoiding pitfalls
Evolution of digitalization under the biopharma environment and its potential in cost down and efficiency improvement

Session A

Antibody Pharmaceuticals

Challenges and considerations in the transition of ADC drugs from bench to bedside
What opportunities have been brought to Chinese biopharma industry after it joined ICH?
Global single-use concept and facilities design
Process of Antibody drug R&D and industrialization
China's biopharma industry under the background of COVID-19 pandemic

Session B

Cell & Gene Therapy

Prospect of cell and gene therapy in solid tumor applications
Optimization and scale-up of free-floating manufacturing process for Adeno-associated virus (AAV) manufacturing
Cost reduction strategies of the off-the-shelf CAR-T products
Effective solutions to produce cGMP "Adeno-associated virus" (AAV) for gene therapy
Implications on costs, pricing, and market presence in the future after launch of multiple products for cell & gene therapy

Call for Papers/presentations

The organizing committee is now calling for papers from all over the world. We welcome high-quality Medical device R&D startups and relevant business personnel such as R&D, design and research experts within the industry to actively contribute reports to the conference, showcase academic achievements and strengthen communication and cooperation.

Please send an email to register, the format of the email is as follows:

Please refer to the reply email received for confirmation of acceptance of the report submitted!

Note: If the report is not accepted, please rest assured that the report will be deleted by the organizing committee confidentially and will not be used for commercial purposes.

Email subject

Report submission + name + company

Content

Report title, abstract, presenter's CV and contact information

Email for registration

Mia.zhu@borscon.com

Application deadline

10 July 2021

SPEAKERS

Zhinan Chen
Chinese Academy of Engineering
Academician

Zixin Deng，Academician
Shanghai Jiao Tong University

Dr. Chenbing Wu
Founder&CEO
EpimAb Biotherapeutics, Inc.

Cuihua liu
Bio-thera
Deputy general manager analysis and preparation research

MingYao Liu
Shanghai Bioray Laboratory
Founder & Chairman

Qicong Hu
BCG Greater China HCPA
Managing Director and Partner

WeiDong Jiang
Shanghai Henlius Biotech
Co-founder Chief Scientific Officer

Weidong Han
Chinese PLA General Hospital
Director of Molecule & Immunology Dept.

Bin Li
Trinomab
Clinical Vice President

Dr. Jijie Gu
Wuxibiologics
Chief Scientific Officer

Grace Zhou Ph.D
ImmVira Pharma Co., Ltd.
Chairman/CEO

LIU Xun
Hengrui Medicine
VP

Dr. XiangYang Zhu
Huabo Biopharm (Shanghai) Co., Ltd.
Xiang Yang Zhu Ph.D.
CEO

Mingde Xia
Innolake Biopharm
Founder, Chairman and CEO

Ruiping Xiao
Founder of Hope Medicine, Chairman of the Board and CEO
Hope Medicine

Bo Shan
CSO
Antengene Corporation

Dr. Michele K. Dougherty
DataRevive USA LLC
Vice President, CMC Biologics

Jia Shi
CMC senior director
EdiGene Biotechnology Co., Ltd

Dr. Mark Chiu
Tavotek Biotech
Founder

Mr. Alex Wu
JW Therapeutics
Senior Vice President (SVP) and Chief Commercial Officer (CCO)

Dr. Wenzhi Tian
ImmuneOnco Biopharma Co., Ltd
Founder and Chairman

Dr. Zhang
Shanghai Mabgeek Biotech
Founder

Richard Wang
Founder, Chairman and CEO
Neukio (ShangHai）Biotherapeutics Co, Ltd

Heidi Gong
Deputy General Manager of clinical production department
Henlius

Jingwu Zang
Founder, Chairman and Director
I-Mab Biopharma

Joe Zhou
Founder and President
Genor Biopharma

Bin Li
Deputy Director of Scientific Research
Shanghai Institute of Immunology

Wubin Pan, Ph.D.
Co-founder, President and Chairman of Board of Directors.
Connect Biopharmaceuticals, Ltd.

Yi Jin
Chief Scientific Officer
Genbase&Genechem

Xiaodong Cheng
Institute of Clinical Immunology, Yue-yang Hospital, Shanghai University of TCM
Professor，Director

Min Wang
PersonGen BioTherapeutics(Suzhou) Co., Ltd
Technical Director

Dr. Alvin Luk
Wuhan Neurophth Biological Technology Limited
CEO&Board Member

YuXuan Wu
Co founder, VP
Researcher, School of life sciences, East China Normal University
Shanghai Bioray Laboratory

李航文

Founder and CEO
斯微生物

Dr.Jiansheng Wu

Vice president of protein science
WuXi Biologics

ZHU ZHENPING
President and CSO
Sunshine Guojian Pharmaceuticals
Director of National Engineering Research Center for antibody drugs
, Director of Shanghai antibody engineering technology research center